T2 Biosystems strong buy rating!
Seite 4 von 10 Neuester Beitrag: 24.05.23 22:16 | ||||
Eröffnet am: | 20.07.16 18:38 | von: Balu4u | Anzahl Beiträge: | 228 |
Neuester Beitrag: | 24.05.23 22:16 | von: Stefanoieder | Leser gesamt: | 91.332 |
Forum: | Hot-Stocks | Leser heute: | 11 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | | 5 | 6 | 7 | 8 | 9 | ... 10 > |
https://www.t2biosystems.com/...patient-with-a-respiratory-infection/
https://finance.yahoo.com/news/...multiyear-innovative-120010744.html
https://www.prnewswire.com/news-releases/...deployment-301029255.html
...Under this agreement, T2 Biosystems is authorized to adapt the CDI-developed COVID-19 test to the T2 Biosystems platform, and market and distribute the test in places of need amid the expanding pandemic...
Mittlerweile gibt`s nur fast 100 Biotechs die allesamt mehr oder weniger mit Covid 19 zu tun haben (wollen). Am Ende ziehen aber nur Wenige das große Los. Also aufpassen!
https://t2biosystems.gcs-web.com/news-releases/...-agreement-covid-19
https://www.biospace.com/article/releases/...coronavirus-sars-cov-2-/
plumper Versuch die Corona-Welle zu reiten
"T2 Biosystems recently announced a licensing agreement to support development of a rapid COVID-19 test..."
die vorläufigen Q1/20 Zahlen sind schlecht:
- Umsatz 2,2-2,6 Mio. $
- davon 0,9-1,1 Mio. $ Produktumsätze (Q1/19 ~ 1,3 Mio. $)
- davon 0,9-1,1 Mio. $ Produktumsätze (Q1/19 ~ 1,3 Mio. $)
- keine Prognose für 2020 (wegen Corona)
Würde mich nicht wundern, wenn wir hier bald eine Kapitalerhöhung sehen würden.
http://investors.t2biosystems.com/news-releases/...ter-2020-financial
"T2 Biosystems intends to adapt the newly licensed COVID-19 test to run on its T2Dx® Instrument, the same instrument used for the FDA-cleared T2Bacteria® and T2Candida® Panels, allowing the detection of both coronavirus and associated secondary bacterial or fungal infections that may lead to sepsis. "
The Company continues to leverage its technology and scientific expertise to aid in the COVID-19 response while prioritizing the health and safety ofits employees and customers. T2 Biosystems recently announced a licensing agreement to support development of a rapid COVID-19 test, developed bythe Center of Discovery and Innovation (CDI) at Hackensack Meridian Health, enabling a larger role in the pandemic response.
The licensed coronavirus assay has been used by healthcare professionals within the Hackensack Meridian Health network, under the U.S. Food andDrug Administration’s Emergency Use Authorization guidance, to test and treat patients suspected of having coronavirus. T2 Biosystems intends toadapt the newly licensed COVID-19 test to run on its T2Dx® Instrument, the same instrument used for the FDA-cleared T2Bacteria® and T2Candida®Panels, allowing the detection of both coronavirus and associated secondary bacterial or fungal infections that may lead to sepsis.